What Works Best to Help Men With Overactive Bladder?
TUESDAY, Jan. 14, 2020 -- Learning how to control the urge to urinate may be all the therapy men need to treat an overactive bladder, a new study suggests.
A combination of drugs and behavioral therapy seems to work better than drugs alone, but... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 14, 2020 Category: General Medicine Source Type: news
Medtronic Wins CE Mark for Rechargeable Sacral Neuromodulation Tech
The sacral neuromodulation market continues to see disruption as Medtronic scores a CE mark for its InterStim Micro neurostimulator and InterStim SureScan MRI leads, clearing the technologies for sale in Europe.
InterStim Micro is a rechargeable device that delivers sacral neuromodulation (SNM) therapy to treat overactive bladder (OAB), fecal incontinence (FI) and non-obstructive urinary retention. It is 80% smaller than the existing recharge-free InterStim II neurostimulator and could reduce the need for battery replacement surgeries due to its life of 15 years. It also features Medtronic'sÂ&...
Source: MDDI - January 14, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Behavioral Therapy First Step for Overactive Bladder in Men
MONDAY, Jan. 13, 2020 -- Among men with overactive bladder, combined behavioral and drug therapy is superior to drug therapy alone, but not behavioral therapy alone, for symptomatic improvement, according to a study published online Jan. 13 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2020 Category: Pharmaceuticals Source Type: news
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec. 30, 2019-- Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 30, 2019 Category: Drugs & Pharmacology Source Type: news
20 Private Medtech Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us.
So without further ado, here are the 20 companies that made the cut:
4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
20 Private Companies to Watch in 2020
MD+DI has taken a hard look at the private medtech sector and developed this list of 20 private companies we will be paying particularly close attention to in the new year. It was not an easy task. There are so many interesting private companies in the industry right now that we started with a much longer list and whittled it down to the 20 companies that stood out most to us.
So without further ado, here are the 20 companies that made the cut:
4C Medical is developing the AltaValve, a transcatheter mitral valve replacement (TMVR) platform designed to address mitr...
Source: MDDI - December 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
MD+DI Readers Rally Behind Axonics for Company of the Year
Last week MD+DI announced Zimmer Biomet as our editors' choice for 2019 Medtech Company of the Year for its impressive turnaround efforts. But as much as we enjoy recognizing our choice each year, it's always fun to see which company is the favorite among our readership.
Out of a whopping 2,651 readers who responded to this year's survey, 45.34% (1,202) voted for Axonics Modulation Technologies out of the 10 finalists. Indeed, 2019 was a critical year for Axonics as it won FDA approval for two indications of its implantable rechargeable sacral neuromodulation&Acir...
Source: MDDI - December 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Medtech in a Minute: Hologic & #039;s Cynosure Flop, Axonics Stands Its Ground, and More
Axonics Not Intimidated by Medtronic
Axonics' implantable rechargeable sacral neuromodulation device is now FDA-approved for the treatment of fecal incontinence, overactive bladder, and urinary retention. Medtronic is suing Axonics for alleged patent infringement, but the company does not appear to be intimidated.
Â
Thermo Fisher May Fancy Qiagen
The rumor mill was lit with a recent Bloomberg report of a potential $8 billion Thermo Fisher-Qiagen deal. Qiagen acknowledged that it has received several "indications of interest" but the company...
Source: MDDI - November 22, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Axonics Isn & #039;t Letting Medtronic Stand in Its Way
For 22 years, the world's largest pure-play medical device company was the only player in sacral neuromodulation, a space that addresses urinary problems as well as fecal incontinence. Now there's a new kid on the block, which has created quite an intense David vs. Goliath medtech story.
For those unfamiliar with the Axonics vs. Medtronic story up to this point, click here for a quick rundown of recent events that have transpired in this market.
Â
FDA Approves Second Indication for Axonics r-SNM
FDA approved the urinary indications for an implantable rechargeable sacral neuro...
Source: MDDI - November 18, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Implants Source Type: news
Urinary Incontinence & OAB | Medscape Urinary Incontinence & OAB | Medscape
Review in-depth clinical information, latest medical news, and guidelines on urinary incontinence, urge incontinence, and adult incontinence. Read about overactive bladder (OAB) and overactive bladder treatment. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news
Cadence Raises $15M in a Healthy and Growing Neuromodulation Market
Cadence Neuroscience is moving to bring a neuromodulation therapy for patients with focal drug-resistant epilepsy to market. The Redmond, WA-based company has raised $15 million in a series A round to help with this goal.
Cadence’s financing round was led by JAZZ Venture Partners, with additional support being provided by Mayo Clinical Ventures, Mayo Benefactors Innovation Fund, and the Epilepsy Foundation of America (EFA).
The device was developed by a Mayo Clinic, Rochester campus Neurology and Neurosurgery team. Cadence is licensing the technology from Mayo and said the device uses chronic subthreshold...
Source: MDDI - November 6, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Medtronic Sues Axonics for Patent Infringement
The medical device industry has seen its share of David vs. Goliath stories over the years, but few have been as intense as the battle between Medtronic and Axonics over the sacral neuromodulation (SNM) market. The story took an unexpected turn this week as Medtronic slapped Axonics with a patent infringement lawsuit that is likely to take years to play out.
Medtronic (the Goliath of this story), filed a lawsuit against Axonics Modulation Technologies (the David of the story), alleging infringement of four patents related to Medtronic's SNM lead placement procedure and implant recharging technologie...
Source: MDDI - November 5, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Implants Source Type: news
Medtronic and Axonics Go Toe-to-Toe in Fast-Growing Sacral Neuromodulation Market
Medtronic and Axonics are getting ready to square off in sacral neuromodulation, a fast-growing market that was monopolized by Medtronic until a month ago.
Last month, Axonics won FDA approval to market its implantable rechargeable sacral neuromodulation (r-SNM) device for the treatment of fecal incontinence, and the company is expected to get FDA approval for overactive bladder and urinary retention any time now. The fecal incontinence approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans without the necessity of having the device explanted.
Medtron...
Source: MDDI - October 8, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
DR ELLIE CANNON: Desperate to avoid constant trips to the loo at night?
DR ELLIE CANNON: For both men and women, overactive bladder syndrome can occur - when the muscle contracts involuntarily, even when the bladder isn't full. (Source: the Mail online | Health)
Source: the Mail online | Health - September 28, 2019 Category: Consumer Health News Source Type: news
Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladder
The approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 26, 2019 Category: Pharmaceuticals Source Type: news
